KDM6B and diabetic kidney disease: Inhibiting lysine demethylase 6b (KDM6B) and 6a (KDM6A) led to elevated H3K27me3 levels in podocytes, which mitigated glomerular disease specifically in diabetic nephropathy models (db/db mice) and in mouse models of Adriamycin-induced nephrotoxicity.